rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    CNTB
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Piper Sandler cuts Connect Biopharma stock price target on launch delay
      Nov 17Investing.comCNTB
      Connect Biopharma Holdings ADR earnings matched, revenue fell short of estimates
      Nov 17Investing.comCNTB
      Connect Biopharma Reports Third Quarter 2026 Financial Results and Provides Business Update
      Nov 16Yahoo FinanceCNTB
      Connect Biopharma Holdings (CNTB) Stock Sees Modest Fair Value Lift After Trial Driven Revisions

      Connect Biopharma Holdings is back in focus after analysts refreshed their price targets, with fair value moving from US$5.88 to US$6.00 in the latest models. The shift follows new Street research that weighs the mixed Phase 2 Seabreeze STAT trial readout, updated Phase III timelines, and a balance of optimism around the asthma pipeline against execution and clinical risk. Read on to see how these revised targets fit into the evolving Connect Biopharma Holdings story and what to watch as the...

      Nov 11Yahoo FinanceCNTB
      Down 25.4% in 4 Weeks, Here's Why Connect Biopharma Holdings (CNTB) Looks Ripe for a Turnaround
      Oct 22Yahoo FinanceCNTB
      Here's Why Connect Biopharma Holdings (CNTB) Could be Great Choice for a Bottom Fisher
      Oct 19Yahoo FinanceCNTB
      Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (MIRM), Connect Biopharma Holdings (CNTB) and Helus Pharma (HELP)

      Detailed price information for Helus Pharma Inc (HELP-Q) from The Globe and Mail including charting and trades.

      Oct 9The Globe and MailCNTBMIRM
      H.C. Wainwright reiterates Buy on Connect Biopharma stock
      Oct 8Investing.comCNTB
      Connect Biopharma COPD Study Shows 81% Cut in Treatment Failures
      Oct 4Yahoo FinanceCNTB
      Wall Street Analysts Are Bullish on Top Healthcare Picks

      Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

      Oct 2The Globe and MailATRACNTB
      Lake Street Sticks to Its Buy Rating for Connect Biopharma Holdings (CNTB)

      Detailed price information for Connect Biopharma Holdings Ltd ADR (CNTB-Q) from The Globe and Mail including charting and trades.

      Oct 1The Globe and MailCNTB
      Why is Connect Biopharma stock surging today?
      Sep 30Investing.comCNTB
      Crude Oil Rises Over 1%; Conagra Brands Earnings Top Views - Conagra Brands (NYSE:CAG), Connect Biopharma

      U.S. stocks mixed: Dow fell over 200 points, while Nasdaq and S&P 500 rose; inflation cooled and Q2 GDP was revised higher.

      Sep 30BenzingaCNTB
      Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Seabreeze STAT Study Evaluating Rademikibart for COPD Exacerbations - Slideshow (NASDAQ:CNTB) 2026-09-30

      2026-09-30. The following slide deck was published by Connect Biopharma Holdings Limited in conjunction with this event.

      Sep 30Seeking AlphaCNTB
      Why Is Connect Biopharma Stock Trading Higher Today? - Connect Biopharma Hldgs (NASDAQ:CNTB)

      Connect Biopharma reports positive Phase 2 results for rademikibart, showing an 81% reduction in COPD treatment failure and high safety.

      Sep 30BenzingaCNTB
      BTIG cuts Connect Biopharma stock price target on trial timeline
      Sep 30Investing.comCNTB
      Connect Biopharma stock jumps on positive COPD trial data
      Sep 30Investing.comCNTB
      Connect Biopharma Reports Positive Phase 2 Rademikibart COPD Data, Plans FDA Talks on Phase 3 Program
      Sep 30Yahoo FinanceCNTB
      12 Health Care Stocks Moving In Wednesday's Pre-Market Session - NewGenIvf Group (NASDAQ:NIVF), Connect B

      Gainers NewGenIvf Group (NASDAQ:NIVF) shares moved upwards by 106.0% to $0.15 during Wednesday's pre-market session. Connect Biopharma Hldgs (NASDAQ:CNTB) stock increased by 79.43% to $1.78. The market value of

      Sep 30BenzingaCNTBNIVF
      Connect Biopharma reports positive phase 2 COPD trial results
      Sep 30Investing.comCNTB
      Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation

      – Rademikibart significantly reduced the rate of treatment failure compared to placebo through one month by 81% (p=0.0122) – – Rademikibart significantly reduced the rate of new moderate to severe COPD exacerbations through one month by 85% (p=0.030) – – Rademikibart significantly reduced the rate of hospitalizations or emergency department visits for new acute COPD exacerbations by 100% (p=0.0137) – – Rademikibart was well tolerated in COPD patients experiencing an acute exacerbation with a low

      Sep 30Yahoo FinanceCNTB
      Nasdaq Gains Over 100 Points; Jabil Posts Upbeat Earnings
      Sep 30BenzingaCNTBNIVFJBL
      Crude Oil Rises Over 1%; Conagra Brands Earnings Top Views
      Sep 30BenzingaCNTBCAG
      Connect Biopharma (CNTB) Misses Key Asthma Trial Goal. Can its Drug Still Move Forward?

      Connect Biopharma Holdings Limited (NASDAQ:CNTB) reported mixed preliminary results on September 15 from its Phase 2 Seabreeze STAT asthma study. Rademikibart produced a numerical 66% reduction in treatment failure over 28 days versus placebo, but the primary endpoint missed statistical significance, with p=0.153. Connect Biopharma Holdings Limited (NASDAQ:CNTB) also reported a lung-function benefit on a […]

      Sep 22Yahoo FinanceCNTB
      Oppenheimer Adjusts Price Target on Connect Biopharma to $5 From $8, Keeps Outperform Rating

      Connect Biopharma Holdings (CNTB) has an average rating of buy and mean price target of $6.52, accor

      Sep 22Yahoo FinanceCNTB
      H.C. Wainwright Sticks to Its Buy Rating for Connect Biopharma Holdings (CNTB)

      Detailed price information for Connect Biopharma Holdings Ltd ADR (CNTB-Q) from The Globe and Mail including charting and trades.

      Sep 22The Globe and MailCNTB
      H.C. Wainwright reiterates Buy on Connect Biopharma stock at $7
      Sep 17Investing.comCNTB
      Canaccord cuts Connect Biopharma stock price target on trial miss
      Sep 16Investing.comCNTB
      Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Rademikibart Phase 2 Study for Acute Asthma Exacerbations - Slideshow (NASDAQ:CNTB) 2026-09-16
      Sep 16Seeking AlphaCNTB
      Why Is Connect Biopharma Stock Trading Lower on Tuesday?
      Sep 15BenzingaCNTB
      Connect Biopharma Rademikibart Phase 2 Data Shows Lung Function Improvement but Primary Endpoint Misses Significance

      Connect Biopharma reported a statistically significant improvement in lung function in its Phase 2 Seabreeze STAT asthma trial, while a 66% reduction in treatment failures did not reach statistical significance. Key Investor TakeawaysConnect Biopharma (NASDAQ:CNTB) said rademikibart produced a statistically significant 130 mL placebo-adjusted improvement in post-bronchodilator FEV1 at Day 7, with a p-value of 0.

      Sep 15Yahoo FinanceCNTB
      Why is Connect Biopharma stock plunging 33% today?
      Sep 15Investing.comCNTB
      Connect Biopharma drops on asthma trial failure (CNTB:NASDAQ)
      Sep 15Seeking AlphaCNTB
      Connect Biopharma reports phase 2 asthma trial results
      Sep 15Investing.comCNTB
      Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adult and Adolescent Participants with Asthma and Type 2 Inflammation

      – Rademikibart meaningfully reduced the rate of treatment failure at 28 days by 66% compared to placebo – –Rademikibart produced a rapid, statistically significant improvement in lung function at Day 7 compared to placebo – – Rademikibart was well tolerated in asthma patients experiencing an acute exacerbation with a low incidence of adverse events– – Data from Seabreeze STAT COPD study of rademikibart will be available later this month after which Connect plans to engage with the U.S. Food and

      Sep 15Yahoo FinanceCNTB
      H.C. Wainwright reiterates Connect Biopharma stock rating at buy
      Sep 14Investing.comCNTB
      Connect Biopharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference

      SAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that Company management will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026 at 11:30 a.m. ET. The live webcast of the presentation may be accessed v

      Sep 3Yahoo FinanceCNTB
      Analysts Offer Insights on Healthcare Companies: Connect Biopharma Holdings (CNTB) and Stryker (SYK)

      Detailed price information for Connect Biopharma Holdings Ltd ADR (CNTB-Q) from The Globe and Mail including charting and trades.

      Aug 28The Globe and MailCNTB
      Connect Biopharma stock rating reiterated at Buy by Canaccord
      Aug 26Investing.comCNTB

      This is the newest page. Registered accounts read further back.